FDA approves oral solution Cuvposa for chronic drooling in children

07/29/2010 | Modern Medicine

The FDA approved Shionogi Pharma's Cuvposa, a flavored liquid form of glycopyrrolate, for the treatment of chronic drooling in patients ages 3 to 16 with neuromuscular disorders. Glycopyrrolate has long been approved for patients with peptic ulcers and to reduce salivation among those under anesthesia.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN